News & Updates

Novel tri-agonist confers significant gains for MASLD patients
Novel tri-agonist confers significant gains for MASLD patients
24 Nov 2023 byAudrey Abella

In a substudy of a phase II obesity trial, individuals with MASLD* and obesity benefited significantly from retatrutide, a once-weekly, injectable, novel synthetic molecule that has shown potent agonist action at GIP**, GLP-1***, and glucagon receptors.

Novel tri-agonist confers significant gains for MASLD patients
24 Nov 2023